ADD/ADHD News

Researchers identified differences in resting-state subcortico-cortical connectivity between youth with and without ADHD by analyzing almost 10,000 functional brain images, according to data published in The American Journal of Psychiatry.

SAN DIEGO — Children with vs. without atopic dermatitis are more likely to experience learning and memory difficulties, according to a poster presented at the American Academy of Dermatology Annual Meeting.

In utero exposure to amphetamine/dextroamphetamine or methylphenidate was not associated with increased risks for neurodevelopmental disorders in children, according to cohort study results published in JAMA Psychiatry.

The FDA has cleared NeuroSigma’s second-generation Monarch eTNS System for treatment of pediatric ADHD, the company announced in a press release.

Some of the most-viewed stories on Healio Psychiatry over the past year highlighted the FDA designating an at-home depression treatment as a breakthrough device as well as the transformative power of psychedelics.

Keratoconus may be associated with ADHD in male patients, according to a study recently published in JAMA Ophthalmology.

Otsuka Pharmaceutical has announced positive outcomes from two 6-week phase 3 clinical trials testing the safety and efficacy of centanafadine for the treatment of ADHD, according to a press release.

ADHD-related medication errors increased almost 300% from 2000 to 2021 among people aged younger than 20 years, a study found.

Amneal Pharmaceuticals has received an abbreviated new drug application from the FDA for its lisdexamfetamine dimesylate capsules to treat ADHD in patients aged 6 years and older and moderate to severe binge-eating disorder in adults.

The FDA has approved multiple first generics of Vyvanse capsules and chewable tablets for ADHD in patients aged 6 years and older, as well as for moderate to severe binge-eating disorder in adults.